Health Catalyst, Inc. (NASDAQ:HCAT) Receives $11.45 Consensus Price Target from Brokerages

Health Catalyst, Inc. (NASDAQ:HCAT) has been assigned a consensus recommendation of “Moderate Buy” from the eleven research firms that are presently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $11.27.

HCAT has been the subject of several research reports. Piper Sandler reiterated an “overweight” rating and issued a $12.00 price target (up from $11.00) on shares of Health Catalyst in a research note on Tuesday, November 26th. Citigroup decreased their target price on shares of Health Catalyst from $10.50 to $10.00 and set a “buy” rating for the company in a research note on Friday, January 10th. Stephens raised their price objective on Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a research report on Thursday, November 14th. Cantor Fitzgerald reissued an “overweight” rating and issued a $16.00 target price on shares of Health Catalyst in a report on Friday, October 4th. Finally, Evercore ISI raised their price target on Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th.

Insider Activity at Health Catalyst

In other Health Catalyst news, CFO Jason Alger sold 19,599 shares of the company’s stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $8.32, for a total transaction of $163,063.68. Following the transaction, the chief financial officer now owns 86,712 shares in the company, valued at approximately $721,443.84. This represents a 18.44 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Daniel Lesueur sold 5,209 shares of Health Catalyst stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $7.70, for a total transaction of $40,109.30. Following the completion of the sale, the chief operating officer now owns 129,690 shares of the company’s stock, valued at $998,613. This represents a 3.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 81,169 shares of company stock valued at $639,174 over the last ninety days. Insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of HCAT. First Light Asset Management LLC grew its stake in shares of Health Catalyst by 438.5% during the 2nd quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock valued at $25,279,000 after purchasing an additional 3,221,408 shares during the period. Impax Asset Management Group plc grew its position in Health Catalyst by 16.4% during the third quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company’s stock valued at $20,793,000 after buying an additional 360,201 shares during the period. Millennium Management LLC increased its holdings in Health Catalyst by 96.3% during the second quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock valued at $15,421,000 after buying an additional 1,184,131 shares during the last quarter. Primecap Management Co. CA raised its position in Health Catalyst by 1.1% in the third quarter. Primecap Management Co. CA now owns 2,404,462 shares of the company’s stock worth $19,572,000 after acquiring an additional 25,000 shares during the period. Finally, Daventry Group LP boosted its stake in shares of Health Catalyst by 3.9% during the 2nd quarter. Daventry Group LP now owns 2,247,053 shares of the company’s stock worth $14,359,000 after acquiring an additional 84,178 shares during the last quarter. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Stock Performance

Shares of HCAT opened at $5.49 on Tuesday. The company has a 50-day simple moving average of $7.56 and a two-hundred day simple moving average of $7.53. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The firm has a market capitalization of $334.07 million, a PE ratio of -4.07 and a beta of 1.36. Health Catalyst has a one year low of $5.35 and a one year high of $10.99.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). The firm had revenue of $76.40 million for the quarter, compared to the consensus estimate of $76.27 million. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The company’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.22) earnings per share. On average, analysts anticipate that Health Catalyst will post -0.33 EPS for the current fiscal year.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.